Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Andrea Veatch (NPI 1952398158)

Field	Value
Entity Type	Individual
Organization	Andrea Veatch
Address	2920 South Meridian
City	Puyallup
State	WA
ZIP	98373
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 3, 2005

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider is clinically focused on oncology infusions and biologic therapies: the top Medicare revenue drivers are high-cost monoclonal antibody and immunotherapy J-codes such as J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab). The presence of chemotherapy administration codes (96413, 96417, 96415) and infusion management codes (96365, 96366, 96375) alongside these J-codes indicates an operation that delivers on-site intravenous oncology treatments rather than primarily office-based management.

Medicare revenue is concentrated: the provider reports Total Medicare revenue of $1.7M and the precomputed top-3 codes account for 72.6% of that Medicare revenue, with J9271 generating $596K, J9144 $294.1K, and J9299 $267.1K. This concentration means a large share of Medicare dollars for this clinician comes from a small number of high-revenue oncology biologics.

This clinician is effectively single-payer at the state level for the available data: there is no Medicaid billing on file, so payer mix for billed claims is dominated by Medicare and the practice has no recorded Medicaid revenue to offset or diversify that Medicare exposure. That lack of Medicaid billing limits comparisons across payers and suggests Medicare reimbursement dynamics will drive revenue risk and negotiation leverage for this provider.

Competitive standing on the largest J-codes is modest rather than dominant: J9271 ranks #702 of 1841 providers nationally (62th percentile; typical, unremarkable volume for this code), J9144 ranks #320 of 615 providers nationally (46th percentile; typical, unremarkable volume for this code), and J9299 ranks #268 of 505 providers nationally (47th percentile; typical, unremarkable volume for this code). Those percentile positions indicate the provider participates in national oncology biologics use at levels that are ordinary for peers, not as a national volume leader.

Office evaluation-and-management activity is a clear outlier relative to national peers: 99215 shows 605 claims with $81.1K revenue and ranks #1176 of 145531 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code), signaling unusually high billing of high-complexity established-patient visits. Paired with the infusion-focused J-code revenue, this suggests the practice combines frequent high-complexity office management with infusion services, amplifying overall Medicare reimbursement per patient.

Ancillary services and throughput metrics are elevated across routine labs and infusion-related codes: 80053 ranks #1618 of 26416 providers nationally (94th percentile), 85025 ranks #2208 of 32833 providers nationally (93th percentile), 36415 ranks #3495 of 86467 providers nationally (96th percentile), and infusion setup/monitoring codes such as 96365 rank #785 of 8873 providers nationally (91th percentile). These high percentiles for lab and infusion encounter codes are consistent with a high-volume infusion clinic model that processes bloodwork and IV infusions frequently.

Tenure is long and may support an established referral base: the provider’s NPI was enumerated on 2005-10-03 (~21 years ago), indicating prolonged activity in the Medicare billing system and suggesting institutional relationships or steady referral patterns could underpin current volumes. Long tenure also increases the relevance of historical utilization trends when evaluating competitive dynamics and capacity.

There are additional high-percentile service codes that reinforce an infusion-heavy practice profile and potential operational capacity: 96372 (injections) ranks #1639 of 58224 providers nationally (97th percentile; notably above typical national volume for this code) and several chemotherapy add-on codes (96417, 96415) show above-typical national participation. Together with the concentration in the top three J-codes, these patterns point to a business model centered on repeated, procedural administration of oncology therapies rather than episodic surgical or inpatient care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

75 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	14,900	$40	$596K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
J9299	Injection, nivolumab, 1 mg	14,060	$20	$267.1K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,900	$30	$98.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	610	$130	$81.1K
J0897	Injection, denosumab, 1 mg	2,760	$20	$52.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$100	$38K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14,840	$1	$29.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	280	$90	$25.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	340	$50	$16.9K

Showing 1–10 of 75

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Andrea Veatch — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

75 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	30	9,600	$40	$465.7K
J9299	5	10	17,740	$20	$404.3K
J9144	4	10	6,480	$40	$357.9K
J1568	4	10	3,750	$30	$152.3K
J0897	53	150	1,800	$20	$57.9K
J3490	14	70	70	$50	$51.2K
88185	21	20	570	$20	$20.1K
J0881	4	30	7,810	$1	$19.8K
96413	11	160	80	$110	$15K
J9217	75	80	90	$130	$14.9K

Showing 1–10 of 75

Related Providers

Other providers that share a Tax Identification Number (TIN) with Andrea Veatch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Manas Agastya	NV	Internal Medicine Physician	$1.6M	$430
Ludmila Martin	WA	Medical Oncology Physician	$1.1M	$0
Ndegwa Njuguna	WA	Hematology & Oncology Physician	$858.1K	$0
Francis Senecal	WA	Hematology & Oncology Physician	$829.9K	$0
Robert Galamaga	AZ	Hematology & Oncology Physician	$749.9K	$0
Jorge Chaves	WA	Hematology & Oncology Physician	$651.5K	$0
Aliakbar Dadla	WA	Hematology & Oncology Physician	$613.3K	$0
Mohammed Kanaan	WA	Hematology & Oncology Physician	$457.3K	$0
David Mccune	WA	Hematology & Oncology Physician	$389.7K	$0
Li Zhang	WA	Hematology & Oncology Physician	$292.8K	$0

Nearby Providers

Other providers in the same ZIP code as Andrea Veatch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kids Choice Dental Puyallup, LLC	WA	Pediatric Dentistry	$0	$8.7M
Kevin Sanders	WA	Radiation Oncology Physician	$4.5M	$0
Total Renal Care Inc	WA	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Sea Mar Community Health Centers	WA	Federally Qualified Health Center (FQHC)	$0	$3.3M
Aaron Rasmussen	WA	Medical Physician Assistant	$449.8K	$19.4K
Jeffrey Newman	WA	Procedural Dermatology Physician	$320.2K	$0
Marina Dolmatova	WA	Family Nurse Practitioner	$268.5K	$0
Sibel Blau	WA	Hematology & Oncology Physician	$258K	$0
Jason Meeker	WA	Dermatology Physician	$216.1K	$0
Brian Kim	WA	Family Medicine Physician	$55.7K	$0

Andrea Veatch — Billing Profile & Reimbursement Data

Sign up for Andrea Veatch — Billing Profile & Reimbursement Data policy alerts

Andrea Veatch — Billing Profile & Reimbursement Data

Sign up for Andrea Veatch — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References